SIGMA-SYSTEMS
4.6.2019 10:02:18 CEST | Business Wire | Press release
Sigma Systems, the global leader in catalog-driven software, is pleased to announce that it has secured a deal to drive the next generation of digital services for one of the largest services providers in Brazil, in partnership with Engineering Do Brasil, a leading IT services provider and a subsidiary of Engineering Ingegneria Informatica S.p.A.
A new digital environment will be created to enable the rapid introduction and seamless selling of new digital offerings to customers across the country. Under the three-year agreement, Sigma Systems, in partnership with Engineering Do Brasil, will provide Sigma CPQ and Sigma Catalog to support the enablement of this new digital infrastructure, thus facilitating a greater level of agility and faster time-to-market for new products and offerings.
Tim Spencer, President and CEO, Sigma Systems, commented : “As a global software provider focused on enabling service providers to innovate quickly and launch new products and services, we are well-placed to support the needs of today’s digital consumer. In partnership with Engineering Do Brasil, we are confident that Sigma Catalog and Sigma CPQ will play a major role in unlocking new opportunities, as it delivers an array of new digital products and services for customers across the country.”
Sigma CPQ (Configure Price Quote), included in the latest edition of the Gartner Magic Quadrant for CPQ , is a telecom-specific, omni-channel quote and order-capture product that enables service providers to sell products, from standardized consumer offerings to complex tailored enterprise services. Deployed in the cloud or on-premise, Sigma CPQ increases the speed and improves the accuracy of sales quotes and orders with an immediate effect on sales efficiency, agility and customer satisfaction.
Deployed in the cloud or on-premise, Sigma Catalog accelerates product innovation to increase revenue from new digital products and new business models.
For further information about Sigma Systems, its award-winning Create-Sell-Deliver portfolio , and getting Next Done NowTM visit sigma-systems.com, or contact us on info@sigma-systems.com .
About Sigma Systems (Twitter @SigmaSystems)
Sigma Systems is the global leader in catalog-driven software solutions for communications, media, and high-tech companies. It serves over 80 customers in 40 countries with its award-winning products. The company’s portfolio spans enterprise-wide Catalog, Configure Price Quote (CPQ), Order Management, Provisioning, Insights and Portfolio Inventory products, and offers a core set of services including professional services, cloud services, and managed services. Sigma utilizes an agile approach to implementing its B/OSS products for its customers. Sigma has offices in North and South America, Europe and Asia Pacific, with technology and integration partners globally.
Additional information can be found online at https://sigma-systems.com/
About Engineering Do Brasil
Engineering Do Brasil is a Consulting and Information Technology global company specialized in Digital Transformation. Through Digital Transformation, Business Integration, Consulting and Outsourcing, Engineering Do Brasil transforms its customers’ operational processes compatible with those of the Digital Era. With more than 39 years of experience in the IT market, more than 10 thousand professionals and projects on more than 10 thousand large customers across various market segments, the experience of our group is being continuously improved by the investment in R&D, with more than 250 researchers, besides several partnerships with the main research centers and universities around the world. More information: https://www.eng.it/ .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190604005371/en/
Contact:
Adnan Bashir Senior Corporate Communications Manager Sigma Systems +1 647-204-0999
Chloe Purcell Head of PR Milner Strategic Marketing Ltd. +44 1473 633123
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom